Nabi-Burza Emara, Drehmer Jeremy E, Hipple Walters Bethany, Rigotti Nancy A, Ossip Deborah J, Levy Douglas E, Klein Jonathan D, Regan Susan, Gorzkowski Julie A, Winickoff Jonathan P
Division of General Academic Pediatrics, Massachusetts General Hospital for Children, Boston.
Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston.
JAMA Pediatr. 2019 Oct 1;173(10):931-939. doi: 10.1001/jamapediatrics.2019.2639.
Despite the availability of free and effective treatment, few pediatric practices identify and treat parental tobacco use.
To determine if the Clinical Effort Against Secondhand Smoke Exposure (CEASE) intervention can be implemented and sustained in pediatric practices and test whether implementing CEASE led to changes in practice-level prevalence of smoking among parents over 2 years.
DESIGN, SETTING, AND PARTICIPANTS: This cluster randomized clinical trial was conducted from April 2015 to October 2017. Ten pediatric practices in 5 states were randomized to either implement the CEASE protocol or maintain usual care (as a control group). All parents who screened positive for tobacco use by exit survey after their child's clinical visit 2 weeks (from April to October 2015) and 2 years after intervention implementation (April to October 2017) were eligible to participate. Data analysis occurred from January 2018 to March 2019.
The CEASE intervention is a practice-change intervention designed to facilitate both routine screening in pediatric settings of families for tobacco use and delivery of tobacco cessation treatment to individuals in screened households who use tobacco.
The primary outcome was delivery of meaningful tobacco treatment, defined as the prescription of nicotine replacement therapy or quit line enrollment. Furthermore, changes in practice-level smoking prevalence and cotinine-confirmed quit rates over the 2 years of intervention implementation were assessed.
Of the 8184 parents screened after their child's visit 2 weeks after intervention implementation, 961 (27.1%) were identified as currently smoking in intervention practices; 1103 parents (23.9%) were currently smoking in control practices. Among the 822 and 701 eligible parents who completed the survey in intervention and control practices, respectively 364 in the intervention practices (44.3%) vs 1 in a control practice (0.1%) received meaningful treatment at that visit (risk difference, 44.0% [95% CI, 9.8%-84.8%]). Two years later, of the 9794 parents screened, 1261 (24.4%) in intervention practices and 1149 (25.0%) in control practices were identified as currently smoking. Among the 804 and 727 eligible parents completing the survey in intervention and control practices, respectively, 113 in the intervention practices (14.1%) vs 2 in the control practices (0.3%) received meaningful treatment at that visit (risk difference, 12.8% [95% CI, 3.3%-37.8%]). Change in smoking prevalence over the 2 years of intervention implementation favored the intervention (-2.7% vs 1.1%; difference -3.7% [95% CI, -6.3% to -1.2%]), as did the cotinine-confirmed quit rate (2.4% vs -3.2%; difference, 5.5% [95% CI, 1.4%-9.6%]).
In this trial, integrating screening and treatment for parental tobacco use in pediatric practices showed both immediate and long-term increases in treatment delivery, a decline in practice-level parental smoking prevalence, and an increase in cotinine-confirmed cessation, compared with usual care.
ClinicalTrials.gov identifier: NCT01882348.
尽管有免费且有效的治疗方法,但很少有儿科诊所识别并治疗家长的烟草使用问题。
确定“抵制二手烟暴露临床行动”(CEASE)干预措施能否在儿科诊所实施并持续开展,并测试实施CEASE干预措施是否会导致2年内家长吸烟率在诊所层面发生变化。
设计、地点和参与者:这项整群随机临床试验于2015年4月至2017年10月进行。5个州的10家儿科诊所被随机分为两组,一组实施CEASE方案,另一组维持常规护理(作为对照组)。所有在孩子临床就诊2周后(2015年4月至10月)以及干预措施实施2年后(2017年4月至10月)通过出院调查筛查出烟草使用呈阳性的家长均符合参与条件。数据分析于2018年1月至2019年3月进行。
CEASE干预措施是一种旨在促进儿科环境中对家庭进行烟草使用常规筛查,并为筛查出的使用烟草的家庭中的个人提供戒烟治疗的实践改变干预措施。
主要结局是提供有意义的烟草治疗,定义为开具尼古丁替代疗法处方或登记戒烟热线。此外,还评估了干预措施实施2年内诊所层面吸烟率和可替宁确认的戒烟率的变化。
在干预措施实施2周后孩子就诊后接受筛查的8184名家长中,961名(27.1%)在干预诊所被确定为当前吸烟者;1103名家长(23.9%)在对照诊所被确定为当前吸烟者。在干预诊所和对照诊所分别完成调查的822名和701名符合条件的家长中,干预诊所中有364名(44.3%)与对照诊所中的1名(0.1%)在该次就诊时接受了有意义的治疗(风险差异为44.0% [95%置信区间,9.8%-84.8%])。两年后,在接受筛查的9794名家长中,干预诊所中有1261名(24.4%),对照诊所中有1149名(25.0%)被确定为当前吸烟者。在干预诊所和对照诊所分别完成调查的804名和727名符合条件的家长中,干预诊所中有113名(14.1%)与对照诊所中的2名(0.3%)在该次就诊时接受了有意义的治疗(风险差异为12.8% [95%置信区间,3.3%-37.8%])。干预措施实施2年内吸烟率的变化有利于干预组(-2.7%对1.1%;差异为-3.7% [95%置信区间,-6.3%至-1.2%]),可替宁确认的戒烟率也是如此(2.4%对-3.2%;差异为5.5% [95%置信区间,1.4%-9.6%])。
在这项试验中,与常规护理相比,在儿科诊所将家长烟草使用的筛查和治疗相结合显示出治疗提供的即时和长期增加、诊所层面家长吸烟率的下降以及可替宁确认的戒烟率的上升。
ClinicalTrials.gov标识符:NCT01882348。